Sol-Gel Technologies Ltd. SLGL: Stock price, financial analysis and comparison with its peers
Stock - SLGL
Sol-Gel Technologies Ltd.
Prices and values in USD currency
Price - $70.4
Price is the close price as of yesterday market close (i.e. 2026-06-01). Prices are not updated in real time.
Sector
Healthcare
Industry
Biotechnology
Employees
55
ISIN
IL0011417206
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead pro... See more...
| SLGL | TNXP | AKTX | EAR | |
|---|---|---|---|---|
| Company Name | Sol-Gel Technologies Ltd. | Tonix Pharmaceuticals Holding Corp. | Akari Therapeutics, Plc | Eargo, Inc. |
| Reason for selection | Selected stock | Stock with min Market Cap difference in Industry | Highest market cap. in industry | Highest market cap. in sector |
| Market Cap | $196 M | $196 M | $1,229,745 M | $1,462,582 M |
| Industry | Biotechnology | Biotechnology | Biotechnology | Medical Devices |
| Sector | Healthcare | Healthcare | Healthcare | Healthcare |
| Total Equity | $23 M | ************************* | ************************* | ************************* |
| Shares Outstanding | 3 M | ************************* | ************************* | ************************* |
| Close | $70.4 | ************************* | ************************* | ************************* |
| Earning Yield | -4.37% | ************************* | ************************* | ************************* |
| ROIC | -58.50% | ************************* | ************************* | ************************* |
| Current Ratio | 4.4 | ************************* | ************************* | ************************* |
| TBI Financial Score | 27 | ************************* | ************************* | ************************* |
| Preferred Stocks | 0 | ************************* | ************************* | ************************* |
| Total Capitalization | $196 M | ************************* | ************************* | ************************* |
| Book Value per Share | 8 | ************************* | ************************* | ************************* |
| Earning Yield EBITavg3 | -9.40% | ************************* | ************************* | ************************* |
| P E (3 years avg) | -13 | ************************* | ************************* | ************************* |
| Net Profit Margin | -31.60% | ************************* | ************************* | ************************* |
| Dividends Yield | nan% | ************************* | ************************* | ************************* |
| Working Capital/Debt | NaN% | ************************* | ************************* | ************************* |
| Net Income | -6127000.0 | ************************* | ************************* | ************************* |
| Net Income 5yGrowth | NaN% | ************************* | ************************* | ************************* |
| Num of Years w Dividends 10y | 0 | ************************* | ************************* | ************************* |
Investment Analysis Report: SLGL and his peers
Overview:
Below you'll find an AI powered output based on the selected companies for comparison. If you change the companies, the output will be re-calculated.
For the analysis we decided to use Graham (father of value investing) as inspiration, the comparison is structured and oriented as the writer did to compare companies back in his times in the chapter 13 of the famous book The Intelligent Investor.
1. Profitability
2. Stability
| Ticker | Stability Max Drop | # Years Statements | # Years Neg Change | Stability Mean Change |
|---|---|---|---|---|
| TNXP | 10 | 0 | NaN% | |
| AKTX | 3 | 0 | NaN% | |
| EAR | 4 | 0 | NaN% |
| Ticker | Rank Stability |
|---|---|
| TNXP | 1.0 |
3. Growth
4. Financial Position
5. Dividends
| Ticker | # years with dividends 10y |
|---|---|
| TNXP | 0 |
| AKTX | 0 |
| EAR | 0 |